Biogen Psoriasis
Earnings Report: Biogen Beats Analyst Estimates, Revenue Rise 10%
|
|
The first targeted biologic therapy for moderate to severe chronic plaque psoriasis.(Amevive from Biogen Inc. ): An article from: Dermatology Nursing $5.95 This digital document is an article from Dermatology Nursing, published by Jannetti Publications, Inc. on October 1, 2003. The length of the article is 1163 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation Detail… |
You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
